作者
Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P Nowacki, Stefano Cascinu, Igor Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, Fortunato Ciardiello
发表日期
2011/5/20
期刊
J Clin Oncol
卷号
29
期号
15
页码范围
2011-2019
简介
Purpose
The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken.
引用总数
学术搜索中的文章
E Van Cutsem, CH Köhne, I Láng, G Folprecht… - J Clin Oncol, 2011